PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-19.03%
Negative net income growth while CRWD stands at 16.90%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
1.61%
Less D&A growth vs. CRWD's 5.35%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
-83.45%
Negative yoy deferred tax while CRWD stands at 170.27%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
6.05%
Less SBC growth vs. CRWD's 20.95%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
130.75%
Slight usage while CRWD is negative at -62.10%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
200.20%
AR growth well above CRWD's 134.73%. Michael Burry would fear inflated sales or less stringent credit controls vs. competitor.
-396.46%
Negative yoy inventory while CRWD is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
-143.28%
Negative yoy AP while CRWD is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-165.97%
Both reduce yoy usage, with CRWD at -64.31%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
103.42%
Some yoy increase while CRWD is negative at -25.11%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-14.22%
Both yoy CFO lines are negative, with CRWD at -91.05%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
16.44%
Some CapEx rise while CRWD is negative at -9.95%. John Neff would see competitor possibly building capacity while we hold back expansions.
-64.41%
Negative yoy acquisition while CRWD stands at 13.24%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-51.47%
Negative yoy purchasing while CRWD stands at 19.16%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
103.41%
Proceeds from sales/maturities above 1.5x CRWD's 5.94%. David Dodd would confirm if the firm is capitalizing on strong valuations or freeing liquidity for expansions.
170.80%
We have some outflow growth while CRWD is negative at -13.24%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
75.53%
Investing outflow well above CRWD's 138.78%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-150.00%
We cut debt repayment yoy while CRWD is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
38.64%
Issuance growth of 38.64% while CRWD is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
-6.02%
We cut yoy buybacks while CRWD is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.